|
Mass. Eye and Ear ophthalmologist receives Senior Scientific Investigator Award
Phys.Org (press release) “I am delighted to have received this support from RPB, which will aid us tremendously in our investigations of ocular surface inflammation in eyes deemed at high risk of corneal transplant rejection,” said Dr. Dana. “With this support, we will be able … |
Organ donation facts and stats – Derbyshire Times
|
Organ donation facts and stats
Derbyshire Times More than 19million people have joined the NHS Organ Donor Register to date, to join them, visit www.organdonation.nhs.uk. Alternatively, you can call the NHS Donor Line on 0300 123 23 23 or text ‘SAVE’ to 84118. Email to a friend; Print this page … |
IncellDx Presents First Study Using Their Novel OncoBreast 3Dx‚Ñ¢ Breast … – PharmiWeb.com (press release)
|
IncellDx Presents First Study Using Their Novel OncoBreast 3Dx‚Ñ¢ Breast …
PharmiWeb.com (press release) About IncellDx, Inc. IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more … |
IncellDx Presents First Study Using Their Novel OncoBreast 3Dx™ Breast … – The Herald | HeraldOnline.com
|
IncellDx Presents First Study Using Their Novel OncoBreast 3Dx™ Breast …
The Herald | HeraldOnline.com … 3Dx platform,” he added. About IncellDx, Inc. IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant … |
Stem Cell Transplant Treats Retinitis Pigmentosa in Mice, Restores Sight – DailyTech
DailyTechStem Cell Transplant Treats Retinitis Pigmentosa in Mice, Restores SightDailyTechScience Stem Cell Transplant Treats Retinitis Pigmentosa in Mice, Restores Sight · Tiffany Kaiser – January 8, 2013 10:06 AM. Print, 1 comment(s) – last by…
IncellDx Presents First Study Using Their Novel OncoBreast 3Dx™ Breast Cancer Technology
IncellDx scientists presented data using IncellDx’s proprietary OncoBreast 3Dx™ technology to multiplex protein markers for tumor type and ER status, markers for her-2 neu protein and mRNA as well as DNA cell cycle and ploidy, all in intact tumor cells in suspension.
Drug dealer walks free from court to save brother's life
A DRUG dealer who faced prison for his third offence in two years has walked free – so he can save his brother’s life.
FDA grants orphan label to eye cancer chemo-delivery combo – FierceDrugDelivery
FDA grants orphan label to eye cancer chemo-delivery comboFierceDrugDeliveryThe company also uses the delivery system in treatments for inflammation associated with cataract surgery, cystoid macular edema, glaucoma, macular degeneration, uveitis and co…
CardioKinetix Initiates Landmark Study of First-of-Its-Kind Treatment for … – PharmiWeb.com (press release)
|
CardioKinetix Initiates Landmark Study of First-of-Its-Kind Treatment for …
PharmiWeb.com (press release) CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, announced the enrollment of the first patients in PARACHUTE IV, the randomized pivotal U.S. trial of the minimally invasive Parachute‚Ñ¢ Ventricular … |
Medistem Inc. Annual Letter to Shareholders – Melodika.net (press release)
Medistem Inc. Annual Letter to ShareholdersMelodika.net (press release)Also, in collaboration with several corporate and academic institutions we published a total of 7 peer reviewed papers in 2012 on collaborative breakthroughs we made in the areas of…